Natural Capsules needs ₹25-30 cr more capex for API. Last year it said it was fully capitalized.
The PE clawback year shifted from FY27 to FY29. Management's API story keeps changing, and the turnaround math is getting harder.
What's new
- Q4 FY26 revenue was ₹58.45 cr, up 55% QoQ, with EBITDA at ₹1.33 cr.
- FY26 net loss was ₹24.66 cr, but operating cash flow was positive at ₹10.92 cr.
- FY27 guidance is ₹274 cr revenue, targeting consolidated profitability but net margin will be 'very low'.
- API revenue target requires ₹25-30 cr additional capex over 2-3 years for balancing clean rooms.
Themes from the call
Credibility
Management's narrative on two fronts — the PE clawback year and the API facility's capex requirement — has shifted without clear explanation.
Margins
API business is growing but EBITDA remains low-single digit or marginally negative; profitability hinges on future regulatory approvals.
Capital allocation
Debt is expected at ₹100-110 cr through FY27-FY28, and the company is evaluating fundraising options including a rights issue.
Guidance watch
- FY27 consolidated revenue guided at ₹274 cr (₹170 cr gelatin, ₹70 cr API, ₹20 cr HPMC, ₹14 cr Fermbox).
- API EBITDA margin guidance is 'low-single digit or marginally negative' despite 3x revenue growth.
- Regulatory pathway for API targets WHO GMP in Q1 FY27, CEP in Q2, and US FDA in Q3-Q4.
Risk flags
- The API revenue story now requires additional, previously unmentioned capex, raising questions about earlier capitalization claims.
- US HPMC demand is frozen by a 68% tariff burden, and management's expectation of normalization in 3-6 months is a hope, not a plan.
- The PE clawback clause's target year has moved two years forward; the implications for founder dilution or cash outflows are unclear.
Key quotes
-
"So that clawback clause is referring to FY'27 actually. FY'27 is a year in which the investor wanted the clawback to be given."
— Natural Capsules management, June 2025 call -
"No, the clawback clause refers to FY29 figures. That is already mentioned in our shareholders' agreement."
— Natural Capsules management, June 2026 call -
"Achieving the 250 crore target is possible with additional investment to ready those balancing clean rooms. About 25-30 crores of expenses would be required."
— Natural Capsules management, June 2026 call
The brief
Natural Capsules is asking investors to fund a turnaround that keeps getting more expensive and less clearly defined. The most striking shift is on the PE investor's clawback clause. In June 2025, management stated the target year was FY27. This quarter, it said the target is FY29. No explanation was offered for the two-year jump, which directly affects how investors model potential cash outflows or dilution.
The capex story has also changed. Management previously said it had fully capitalized the API facility for a revenue potential of ₹240-300 crore. Now, it says achieving the ₹250 crore target requires an additional ₹25-30 crore in capex for balancing clean rooms. The need for more capital was not disclosed in prior calls.
Operationally, there is a nascent recovery. Q4 revenue jumped 55% QoQ to ₹58.45 crore, and the company reported positive operating cash flow of ₹10.92 crore for the full year despite net losses. The API plant started commercial production with ₹9 crore in Q4 revenue. But the API business is still EBITDA-negative, and management admits it won't hit double-digit margins until it secures WHO, EU, or US certifications — a process that takes years.
The FY27 guidance of ₹274 crore revenue looks achievable if the capsule business holds steady, but it bakes in an optimistic view of regulatory timelines and tariff relief for HPMC. The company's total debt is projected at ₹100-110 crore through FY28, and it is evaluating fundraising options including a rights issue, with promoters reluctant to dilute.
The turnaround thesis now rests on multiple moving parts: resolving two narrative inconsistencies, executing a multi-year regulatory approval process, and finding funding without major dilution. The market is being asked to trust a plan that has already been revised upward in cost and outward in time.
Natural Capsules' turnaround requires more money and more time than management previously said. The explanations keep changing.